Marketing Authorization For Oral Spleen Tyrosine Kinase Inhibitor Tavalisse In South Korea

Kissei Pharmaceutical

21/01/2025 02:31

Jan 21 (Reuters) - Kissei Pharmaceutical Co Ltd  4547.T :
    * KISSEI PHARMACEUTICAL CO LTD - MARKETING AUTHORIZATION FOR ORAL SPLEEN
TYROSINE
KINASE INHIBITOR TAVALISSE IN SOUTH KOREA

Source text:  ID:nTSmu87067 
Further company coverage:  4547.T